Computational analysis of epigenetic patterns facilitates diagnosis of unknown hereditary disorders
A new sophisticated computational model, developed by scientists at Lawson Health Research Institute, is bringing an innovative method of diagnosing rare hereditary conditions.
Genome-wide testing of DNA methylation, a mechanism of the epigenome, has been shown to facilitate the diagnosis of previously unsolved cases of neurodevelopmental or congenital abnormalities. The epigenome is any process that can change the expression of a gene without changing the gene sequence.
The latest in a series of research publications around the theme of epigenomic testing applied the new pattern recognition model to DNA samples of 965 patients with neurodevelopmental and congenital anomalies that did not have a definitive diagnosis despite extensive clinical genetic testing. Their DNA, acquired through blood samples, was examined using the new model, and dozens of new cases were resolved.
Current testing of patients who present with neurodevelopmental and congenital anomalies leaves a number of cases undiagnosed or unexplained. “Many families spend years going through repeated testing and assessments, in search of a diagnosis. This process is hard on patients and families, and is a great cost to our health care system,” explains Dr. Bekim Sadikovic, Associate Scientist at Lawson, and Head of the Molecular Genetics Division in the Department of Pathology and Laboratory Medicine, London Health Sciences Centre (LHSC).
While currently there are limited treatment options associated with many of these conditions, providing a specific diagnosis can help physicians better predict the course of the disease, allowing for better planning and support for the patient. This research highlights the value of epigenomic testing in the routine assessment of neurodevelopmental and congenital disorders.
From this research, LHSC will be the first site in the world to offer this type of genetic testing. “We are excited to make this testing accessible to local patients, and across the world. Our lab has partnered and licensed this technology to Greenwood Genetics Laboratories in the United States and Amsterdam University Medical Centre Laboratories in the European Union”, says Dr. Sadikovic. 100 per cent of revenue will be funneled back to support local testing for patients and ongoing research.
Learn more: Research leads to new molecular diagnostic tool
The Latest on: Molecular diagnostic tool
[google_news title=”” keyword=”molecular diagnostic tool” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Molecular diagnostic tool
- Infectious Disease Diagnostic Market: Projected to Reach $39,941.37 Million by 2030on May 16, 2024 at 5:00 pm
These diagnostic tools are crucial for the timely and accurate identification ... Detecting the flu typically involves rapid influenza diagnostic tests (RIDTs), molecular tests like PCR, and assessing ...
- Integrated DNA Technologies and Molecular Health Ink Commercial Partnershipon May 15, 2024 at 6:41 am
Our partnership with Molecular Health reflects another step toward our goal of delivering on our customers' needs and solving their problems by equipping them with a more efficient path to advance ...
- Exploring Frontiers: Molecular Diagnostics and Therapeutics Insightson May 15, 2024 at 6:26 am
We are now entering the third decade of the 21st Century, and, especially in the last years, the achievements made by scientists have been exceptional, leading to major advancements in the ...
- Europe In Vitro Diagnostics (IVD) Market Overview, Top Key Players, Growth, Size, Share, and Forecast 2024 to 2032on May 14, 2024 at 3:48 pm
Report Ocean has published a new report on the “Europe In Vitro Diagnostics (IVD) Market” in diverse regions to produce a report with more than 250+ pages. This market report is an excellent fusion of ...
- Global In Vitro Diagnostics (IVD) Market Upcoming Trends, Size, Key Players, Revenue, Share, and Forecast to 2024 to 2032on May 14, 2024 at 3:46 pm
Report Ocean has published a new report on the “Global In Vitro Diagnostics (IVD) Market” in diverse regions to produce a report with more than 250+ pages. This market report is an excellent fusion of ...
- QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision supporton May 14, 2024 at 1:52 pm
QIAGEN Clinical Insight Interpret is the first NGS interpretation platform to be certified under IVDR for both oncology and hereditary applications. As a medical device software for clinical decision ...
- AI's Transformative Power In Healthcare Diagnosticson May 14, 2024 at 11:32 am
Even though AI in healthcare diagnostics continues to evolve from the standpoint of its capabilities and challenges, its increasing impact is undeniable.
- QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Pluson May 14, 2024 at 7:08 am
QIAGEN N.V. QGEN recently secured FDA clearance for the QIAstat-Dx Respiratory Panel Plus syndromic test. Previously authorized under the FDA Emergency Use Authorization (“EUA”) as the QIAstat-Dx ...
- Northwell opens $3.2M molecular diagnostics laboratoryon May 9, 2024 at 7:05 am
The 2,800-square-foot facility is designed to identify targeted cancer therapies. Northwell said that the lab will enhance the ability to accurately diagnose and provide a prognosis for cancer ...
- Sapio Sciences Unveils Enhanced Molecular Biology Toolkiton May 7, 2024 at 7:44 am
Sapio ELN release 24.5 features multiple improvements, including enhanced CRISPR design with multiple sequence alignment and integration with small molecule research. Image Credit: Nuttapong ...
via Bing News